February 5-28, 2022
Boston Convention & Exhibition Center
Boston, MA, USA
February 5-28, 2022
Boston Convention & Exhibition Center
Boston, MA, USA
This one day, hands-on course will introduce the use of the open source software KNIME for data analysis and data visualization. KNIME does not require any programming skills as the user interacts with data by building in a graphical interface pipelines of nodes each executing a separate step, allowing the participant to interact with data in a much more natural way. KNIME allows scientists with no programming skill to apply advanced statistical methods to their data as well as integrates several programming languages allowing novel or domain-specific algorithms to be integrated into graphical workflows. Data scientists and bioinformaticians developing analytical solutions for non-coders can therefore implement cutting-edge algorithm that can still be easily executed by their users. Data scientists and bioinformaticians can therefore concentrate on solving new problems instead of executing code for their users.
The course comprises two parts. In the morning, attendees will be taught the basics of KNIME, how to load data, select rows and columns, aggregate data and learn visualization techniques. In the afternoon, an introduction into multi variate analysis using KNIME will be given, such as how to calculate various correlations, normalize data, cluster data and use machine learning to analyze biological data. Attendees are strongly encouraged to bring their own data, as at the end of the day they will have the occasion to start an analysis pipeline on their own.
Marc Bickle
Max Planck Institute of Molecular Cell Biology and Genetics
Marc Bickle obtained his Ph.D. at the Biozentrum of the University of Basel (Switzerland) working on the immunosuppressive drug Rapamycin using yeast. He then went to the LMB in Cambridge, U.K., to study the molecular mechanism underlying behavior in C. elegans. He then participated in the creation of Aptanomics, a Biotech doing drug discovery in oncology in Lyon, France. He developed screening methods for peptide aptamers-guided drug discovery programs. He then headed the High-Content Screening facility of the Max Planck Institute in Dresden, Germany (TDS, MPI-CBG), developing image-based (CRISPR/RNAi/drugs) screens in live cell, 3D-cell cultures and small organisms. He is currently leading the Organoid Phenotyping platform of the Institute of Translational Bioengineering (ITB) of Roche.